Sign in
CompletedPhase 2

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol

Key facts

Who runs it
Charite University, Berlin, Germany
Where
Germany4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
170 people enrolled
Started
1 Oct 2020
Ended
2 Jan 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BX-1
  • Placebo
Record updated
13 August 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Diagnosis of posttraumatic stress disorder (PTSD) according to DSM 5 with a 20 item CAPS-5 total score ≥ 26
  • At least two nightmares a week, an intensity score ≥ 2, with a CAPS-IV B2 (frequency and intensity for the last week) score ≥ 5
  • Men and women between 18 and 65 years of age
  • Written informed consent
  • The patient has the capacity to give consent (He/she is able to understand the nature and anticipated effects/side effects of the proposed medical intervention)
  • The patient is not breastfeeding
  • Women of child-bearing potential must have a negative urine or serum pregnancy test
  • All participants must use highly effective contraception
  • The patient received stable pharmacological medication for at least 4 weeks prior to study entry (any changes in medication dose or frequency of therapy must be answered with no)

Who cannot take part

  • Trauma-focused psychotherapy four weeks before the trial
  • Initiation of sleep medication 4 weeks prior screening or initiation of alpha adrenergic agents 4 weeks prior to screening
  • The patient did participate in other interventional trials during the 3 months before and at the time of this trial
  • Lifetime cannabis use disorder
  • Current substance/alcohol use disorder (≤ 3 months)
  • Psychotic disorder
  • Bipolar disorder
  • Dementia
  • Acute or unstable medical illness
  • Epilepsy
  • Relevant heart diseases
  • Known HIV- and/or active Hepatitis-B- or Hepatitis-C-infection
  • Current or past malignant illness
  • The patient does have a known allergy or contraindication against Dronabinol
  • The patient does have clinically significant laboratory abnormalities
  • Acute suicidality
  • Current anorexia nervosa
  • Current major depressive episodes and a MADRS score > 29
  • The patient is unwilling to consent to saving, processing and propagation of pseudonymized medical data for study reasons
  • Patients, who may be dependent on the sponsor, the investigator or the trial sites, have to be excluded from the trial
  • The patient is legally detained in an official institution
  • The patient does have clinically significant abnormalities in 12-lead ECG

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized controlled exploratory phase II trial will test the hypothesis that oral dronabinol improves nightmares (primary outcome) and other PTSD symptoms (secondary outcomes) to a greater extent than placebo over a ten week intervention phase in a parallel group design.

The 2 groups in the trial

  • BX-1 (dronabinol)Treatment being tested

    BX-1

    Treatment: BX-1

  • PlaceboPlacebo, for comparison

    Placebo of BX-1

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol: A Randomized Controlled Study (THC PTSD-trial)
Publications
Record updated
13 August 2025